Anti-human NGF antibody and its preparation method and use
A technology of antibodies and antigens, applied in botany equipment and methods, biochemical equipment and methods, antibodies, etc., can solve the problems of different antibody tolerance speed and toxicity, pharmacokinetic changes, and different immunogenicity, etc., and achieve clinical The effects of reduced dosage, strong specificity, and high yield
Active Publication Date: 2022-06-28
AMPSOURCE BIOPHARMA (SHANGHAI) INC +1
View PDF14 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
The immunogenicity of different CDRs is different, resulting in different antibody tolerance speed and toxicity, which directly affects the efficacy of the drug
On the other hand, the subject's immune response to the antibody itself will form immune complexes, which will alter the pharmacokinetics and produce allergic reactions, etc., eliminating its therapeutic use
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment Construction
[0048] Abbreviations and Definitions
[0049] hNGF human nerve growth factor
[0050] CDRs Complementarity Determining Regions in Immunoglobulin Variable Regions Defined by the IMGT Numbering System
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More
Abstract
The invention provides an antibody combined with NGF or an antigen-binding fragment thereof, and lists the amino acid sequences of the heavy chain and light chain variable regions of the antibody. The NGF antibody or antigen-binding fragment thereof provided by the invention has higher affinity to NGF and can effectively block the binding between NGF receptors and NGF. The antibody or its antigen-binding fragment can inhibit the binding activity of NGF and receptors in vitro, and is suitable for treating pain diseases related to the hyperexpression and level increase of NGF.
Description
technical field [0001] The present invention relates to the field of therapeutic monoclonal antibodies, more particularly, to an anti-NGF antibody or an antigen-binding fragment thereof and uses thereof. Background technique [0002] Nerve Growth Factor (NGF) is the first neurotrophic factor to be discovered. It has the dual biological functions of neuron nutrition and neurite outgrowth. The expression of characteristics has an important regulatory role. NGF contains three subunits, α, β, and γ. The β subunit is the active subunit of NGF that plays the role of nerve regeneration and repair. Currently known NGF receptors include a high-affinity tyrosine kinase receptor (Tropomyosin receptor kinase A, TrkA) and a low-affinity p75 neurotrophin receptor (p75Neurotrophin Receptor, p75NTR). [0003] Although initially the primary role of NGF was to promote neuronal survival and differentiation, an increasing number of studies over the last two decades have shown that NGF is asso...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/22C12N15/13A61K39/395A61P29/00A61P19/02A61P13/10A61P19/08A61P25/02
CPCC07K16/22C12N15/85C12N5/0682A61P19/02A61P29/00A61P13/10A61P19/08A61P3/10A61P25/02C07K2317/565C07K2317/56C07K2317/24C07K2317/567C07K2317/76C12N2800/107C12N2510/00A61K2039/505
Inventor 王著高永娟陈思周若芸郑云程孙乃超李强
Owner AMPSOURCE BIOPHARMA (SHANGHAI) INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com